Terapia cellulare CAR-T in un paziente affetto da linfoma mantellare recidivato/refrattario

The availability of this first cell therapy for relapsed or refractory mantle cell lymphoma provides an important option for patients. At present, treatment options for these patients, whose disease progresses after initial therapies, are almost nil. Thus, there is a felt need for new treatment options. The high response rates observed in the registrational study and confirmed by real-life data support the potential of KTE-X19 as an effective therapy for patients with relapsed or refractory mantle cell lymphoma, with a manageable safety profile.